Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes

Journal of Virology

Volumn 74, Issue 22, 2000, Pages 10670-10680

  Nyambi, P N ^a   Nadas, A ^a   Mbah, H A ^a   Burda, S ^a   Williams, C ^a   Gorny, M K ^a   Zolla Pazner, S ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EPITOPE; MONOCLONAL ANTIBODY; VIRUS GLYCOPROTEIN;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CLUSTER ANALYSIS; GENETIC CONSERVATION; GENETIC VARIABILITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; MATHEMATICAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; VIRION; VIRUS TYPING;

ANTIBODIES, MONOCLONAL; CLUSTER ANALYSIS; GENOTYPE; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; VIRION;

EID: 0033765904     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.22.10670-10680.2000     Document Type: Article

References (52)

1. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity
2. Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation
3. Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions
4. Neutralization of primary human immunodeficiency virus type 1 virus isolates by the broadly reactive anti-V3 monoclonal antibody 447-452D
5. Evolution and polymorphism of poliovirus genomes
6. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations
7. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
8. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins
9. Neutralization of diverse HIV-1 variants by an anti-V3 human monoclonal antibody
10. Generation of human monoclonal antibodies to HIV
11. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades
12. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity
13. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120
14. Genetic divergence of poliovirus strains isolated in the Karachi region of Pakistan
15. Genetic and phylogenetic analysis of env subtypes G and H in Central Africa
16. Further evidence of the presence of genetically aberrant HIV-1 strains in Cameroon and Gabon
17. Three-year follow-up of vaccine response in extremely pre-term infants
18. Serotype-specific identification of poliovirus by PCR using primers containing mixed-base or deoxyinosine residues at positions of codon degeneracy
19. Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: Identification of a new subtype designated subtype I
20. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement
21. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies
22. Spectral mapping, a technique for classifying biological activity profiles of chemical compounds
23. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes
24. Potent and synergistic neutralization of human immunodeficiency virus type 1 (HIV-1) primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
25. Two antigenically distinct subtypes of HIV-1: Viral genotype predicts neutralization immunotype
26. The discovery of the enterovirus and the classification of poliovirus among them
27. The emergence of simian/human immunodeficiency viruses
28. Binary classification by stochastic neural nets
29. Hidden Markov models and some connections with artificial neural nets
30. Genetic subtypes of HIV-1 in Cameroon
31. Mapping of epitopes exposed on intact HIV-1 virions: A new strategy for studying the immunologic relatedness of HIV-1
32. Study of the dynamics of neutralizing escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus (SIVcpz-ant)
33. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M
34. Multivariate analysis of human immunodeficiency virus type 1 neutralization data
35. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type-1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses
36. The neutralization relationship of HIV type 1, HIV type 2, and SIVcpz is reflected in the genetic diversity that distinguishes them
37. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex
38. Extent of antigenic diversity in the V3 region of the surface glycoprotein gp120 of human immunodeficiency virus type 1 group M and consequences for serotyping
39. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants
40. The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominately directed against a variable, discontinuous epitope presented by the gp120 V3 domain
41. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O
42. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120
43. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
44. The majority of neutralizing Abs in HIV-1 infected patients recognize linear V3 loop sequences
45. Neutralization serotypes of HIV-1 field isolates are not predicted by genetic subtype
46. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies
47. The implications of antigenic diversity for vaccine development
48. Immunotyping of HIV-1: An approach to immunologic classification of HIV
49. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry